

## IFW 3623

## INFORMATIÖN PIŠCLOSURE STATEMENT TRANSMITTAL

To Commissioner For Patents: Enclosed herewith is a Form PTO-1449, any required copies of documents listed thereon, and any concise replanation of their relevance is indicated below per 37 CFR 1.97.

Signature

Application Number	10/501,832	_
Filing Date	July 19, 2004	_
First Named Inventor	Folkert G. Miedema	
Group Art Unit	3623	_
Examiner Name	N/A	
Attorney Docket Number	NI 020039	_

February 8, 2006

X Please charge any required fee under § the issue fee) to Account No. 14-1270.	1.17(i) or §1.17(p) or any other required fee (except
--	---

- I certify that these documents were first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months ago.
- I certify that none of these documents were cited in any communication from a foreign Patent Office
  in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable
  inquiry, none of these documents was known to any individual designated in §1.56(c) more than three
  (3) months ago.
  - [] Applicant hereby petitions under §1.97(d) that this IDS be considered after final Action or Notice of Allowance, pays the fee under §1.17(p) as indicated below, and I certify 1. or 2. as indicated above.
  - [] A fee under §1.17(p) is not required under §1.97(c), after the first Action on the merits and more than (3) months after the date of application or RCE, because I certify 1. or 2. as indicated above.
  - A copy of the citations is not reguired because they were previously submitted or cited in the parent application (or in U.S. patent application Ser. No. \_\_\_\_\_\_\_ Filing Date \_\_\_\_\_\_\_ relied on for an earlier effective filling date under 35 U.S.C. 120).
  - Acopy of the U.S. patent(s) and patent application publication(s) in all U.S. national patent applications filled after June 30, 2003, and in all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003 under 37 CFR 1.491(b), are to required.
  - A concise explanation of the relevance of each non-English document, as understood by the individual designated in §1.56(c) most knowledgeable about the contents, is enclosed per §1.98(a)(3).

The concise explanation of the relevance of any document, as understood by the individual designated in  $\S 1.56(c)$  most knowledgeable about the contents, is that the document is/was:

- cited in the specification or considered in drafting the specification of this application:
- Cited as an "X", "Y", or "A" document in a foreign Patent Office search report in a foreign counterpart application.

DM.CI

SIGNATIVE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Priet Type)

Michage Marion

Registration No. (Attorney/Agent)

32,266

Signature

Date

February 8, 2006

CERTIFICATE OF MAILING OR TRANSMISSION

Thereby certify that this is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. BOX 1450 Alexandria, VA 2231-1450, or facsimile transmitted to the U.S. Patent and Trademark Office let. # 703-872-9306 on the date below:

Name (Priet Type)

Patti DeMichele

SIPE FEB 13 2006 Substitute for form 1449/PTO

PTO/SB/08A (08-03) Approved for use through 07/31/2006, 0MB 0551-0315
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
re required to respond to a collection of information uncless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Co	iipiete ii Kriown		
	Application Number	10/501,832		
	Filing Date	July 19, 2004		
	First Named Inventor	Folkert G. Miedema		
	Art Unit	3623		
	Examiner Name	N/A		
_	Attomore Dooked Museban	NII 0000000		

	D	lame of Patentee or	1000	U. S. PATEN¹ Publication Date	Document Number	Cite	Examiner
, Columns, Lines, Where ant Passages or Relevant Figures Appear	Relevant Pa	cant of Cited Document		MM-DD-YYYY	Number-Kind Code <sup>2 (Fknown)</sup>	Cite No.1	initials*
			Ginte	04-06-1999	us- 5,892,900		
					US-		
					US-		
					US-		
			t	<u> </u>	US-		
	<del> </del>		1-		US-		
	-		+		US-		
			+-		US-	-	
	-		+		US-		
			+-	<u> </u>	US-	-	
			+		US-		
			+		US-		
	<del>                                     </del>		+	<del> </del>	US-	-	
			+	<del> </del>	US-	-	
	<del>                                     </del>		+	<del> </del>	US-	-+	
			+	-	US-	-+	
	<b>_</b>		+-	<del> </del>	US-		
	-		+	ļ		- 1	
			-			- 1	
					US-	-	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>0</sup>	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)		Applicant of Orca Document			
						Г	
						Т	

/Maria Vanderhorst/ 03/27/2008

"EXAMINER: Initial if reference considered, whether or not clasion is in conformance with MPEP 659. Draw line through clasion if not in conformance and not considered, include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPT0 Petrol Comments at www.uspido.copy or MPEP 801 01.4. \*Enter Officion this issues the document, by the two-letter code (NIPIP Standard ST 3). \*For Apparese patient document, the indication of the year of the regno of the Emperor must precede the serial number of the patient document. When the document under the option of the patient is a price as a price of the patient document. The option of the patient is a price as a price of the patient approach is a price as a price of the patient approach. The patient is a price as a price of the patient approach is a price as a price of the patient approach. The patient is a price as a price of the patient approach is a price as a price of the patient approach is a price of the patient approach. The patient is a price as a price of the patient approach in the patient approach is a price of the patient approach. The patient approach is a price of the patient approach is patient. The patient approach is a price of the patient approach is patient. Translation is attached.

Transaction is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 USC. 122 and 37 CFR 1.14. This collection is estimated to take You to compiled. The collection of the process of the control of the process of the pr TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 6651-0331
U.S. Patent end Trademark Office, U.S. DEPARTMENT OF COMMERCE
are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use es many sheets as necessary)

Sheet 1

Examiner	Date	
Signature	Considered	
	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through ditation if not in conformance end not considered. Include copy of this form with next communication to epplicant.

1 Applicants unique citation designation number (optional). Applicant is to place a check mark here If English Inerguage Translation is attained.

This collection of information is required by 37 CFR 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) on application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including pathering, preparing, and submitting the completed applications from the to USPTO. Time with very depending upon the included use. Any comments on the pathering preparing, and submitting the completed applications from the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments on the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very depending upon the included use. Any comments of the USPTO. Time will very dependent upon the USPTO. Time will very dependent upo

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.